These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20541691)

  • 41. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
    Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
    Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidemiology of adverse cutaneous reactions to drugs.
    Stern RS; Steinberg LA
    Dermatol Clin; 1995 Jul; 13(3):681-8. PubMed ID: 7554515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Neither skin tests nor challenge tests are sufficient to provide formal diagnosis of drug allergy or sensitisation. A discussion of the article "Two medicines of similar imputability in dermal adverse drug reactions (two cases): the limitations of epicutaneous testing?" by P. Dellestable et al].
    Augey F; Guneraa-Saad N; Bérard F; Nicolas JF
    Ann Dermatol Venereol; 2008 Dec; 135(12):867-8. PubMed ID: 19084703
    [No Abstract]   [Full Text] [Related]  

  • 44. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy.
    Mockenhaupt M
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):142-60; quiz 161-2. PubMed ID: 19371237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New cutaneous side effects of drugs].
    Meurer M
    Hautarzt; 2010 Aug; 61(8):649. PubMed ID: 20644903
    [No Abstract]   [Full Text] [Related]  

  • 47. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.
    Shenton JM; Teranishi M; Abu-Asab MS; Yager JA; Uetrecht JP
    Chem Res Toxicol; 2003 Sep; 16(9):1078-89. PubMed ID: 12971795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The diagnostic value of atopy patch testing and prick testing in atopic dermatitis: facts and controversies.
    Lipozencić J; Wolf R
    Clin Dermatol; 2010; 28(1):38-44. PubMed ID: 20082949
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Importance of valid measurements of benefit and risk.
    Spitzer WO
    Med Toxicol; 1986; 1 Suppl 1():74-8. PubMed ID: 3821430
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cutaneous drug reactions in intensive care.
    Bigham C; Elsey A
    Br J Hosp Med (Lond); 2013 Jun; 74(6):340-6. PubMed ID: 24049830
    [No Abstract]   [Full Text] [Related]  

  • 51. Methods for Identifying Culprit Drugs in Cutaneous Drug Eruptions: A Scoping Review.
    Bose R; Ogbalidet S; Boshra M; Finstad A; Marzario B; Huang C; Fahim S
    J Cutan Med Surg; 2022; 26(2):162-168. PubMed ID: 34798794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of Sensitivities of Skin Prick and Intradermal Tests with Oral Rechallenge Test: A Prospective Interventional Hospital-Based Study.
    Singh SK; Bohara A; Rai T
    Indian J Dermatol; 2021; 66(1):55-59. PubMed ID: 33911294
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Impressive erythema, burning and vesicles in light exposed skin area. Sunburn or phototoxic reaction?].
    Klein F
    MMW Fortschr Med; 2009 Sep; 151(37):12-4. PubMed ID: 19827417
    [No Abstract]   [Full Text] [Related]  

  • 54. [Clinical practise guideline of the special interest group in allergy of the ÖGDV - Drug provocation testing in the diagnosis of cutaneous drug reactions].
    Kränke B; Aberer W; Egger C; Hawranek T; Reider N; Volc-Platzer B; Wöhrl S;
    Wien Klin Wochenschr; 2011 Oct; 123(19-20):585-91. PubMed ID: 21901272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intentional rechallenge: does the benefit outweigh the risk?
    Stanulović V; Venegoni M; Edwards B
    Drug Saf; 2013 Mar; 36(3):155-61. PubMed ID: 23430570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Length of treatment. Three questions for prescribers.
    Aronson JK; Ferner RE
    BMJ; 2010 Sep; 341():c5013. PubMed ID: 20843922
    [No Abstract]   [Full Text] [Related]  

  • 57. What appears safe is sometimes not: a reason for caution.
    Bachow SH; Lamanna N
    Blood; 2016 May; 127(20):2367-8. PubMed ID: 27207319
    [No Abstract]   [Full Text] [Related]  

  • 58. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice.
    Little DT; Ward HR
    J Investig Med High Impact Case Rep; 2014; 2(4):2324709614556129. PubMed ID: 26425627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects.
    Perricone C; Colafrancesco S; Mazor RD; Soriano A; Agmon-Levin N; Shoenfeld Y
    J Autoimmun; 2013 Dec; 47():1-16. PubMed ID: 24238833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cystoid macular edema associated with preservative-free latanoprost after uncomplicated cataract surgery: case report and review of the literature.
    Makri OE; Tsapardoni FN; Plotas P; Ifantis N; Xanthopoulou PT; Georgakopoulos CD
    BMC Res Notes; 2017 Mar; 10(1):127. PubMed ID: 28320481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.